Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat

Tadanobu Utsuki, Mohammed Shoaib, Harold W. Holloway, Donald K. Ingram, William C. Wallace, Vahram Haroutunian, Kumar Sambamurti, Debomoy Lahiri, Nigel H. Greig

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Reports of an inverse relationship between nicotine intake, due to cigarette smoking, and the incidence of Alzheimer's disease (AD) prompted us to investigate the effects of nicotine on amyloid β-protein precursor (AβPP) processing in rat. Overproduction and/or altered metabolism of AβPP, resulting in increased amyloid β-peptide (Aβ), appear pivotal in the pathogenesis of AD. Aβ is generated proteolytically from AβPP by a group of secretases. AβPP cleavage by γ-secretase results in the secretion of a truncated soluble AβPP (sAPPγ) that contains intact Aβ. Nicotine, 1 and 8 mg/kg/day, doses commensurate with cigarette smoking and a higher but well tolerated dose, respectively, was administered over 14 days and Western blot analysis was performed on sAPP fragments. Both doses significantly reduced sAPPγ. These actions were blocked by nicotinic receptor antagonism. Whereas nicotinic antagonists alone had no effect on either total sAPP or sAPPγ levels in CSF, muscarinic antagonism significantly elevated them; suggesting that muscarinic rather than nicotinic receptor silence alters processing of AβPP to favor a potentially amyloidogenic route. Combined nicotine and muscarinic antagonism attenuated the action of the latter to elevate sAPPγ, indicating that nicotine modifies AβPP processing away from potentially amyloidogenic products. These results suggest that within the brain, levels of total sAPP, sAPPγ and, accordingly, Aβ are subject to cholinergic manipulation, offering therapeutic potential at the level of AβPP processing to decrease Aβ deposition.

Original languageEnglish
Pages (from-to)405-415
Number of pages11
JournalJournal of Alzheimer's Disease
Volume4
Issue number5
StatePublished - Oct 2002

Fingerprint

Amyloid beta-Protein Precursor
Nicotine
Amyloid
Peptides
Cholinergic Agents
Amyloid Precursor Protein Secretases
Nicotinic Receptors
Alzheimer Disease
Smoking
Nicotinic Antagonists
Western Blotting
Incidence
Brain

Keywords

  • β-peptide
  • Alzheimer's dementia
  • Amyloid
  • Cholinergic system
  • Neuroprotection
  • Nicotine drug abuse
  • Scopolamine
  • Smoking

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Utsuki, T., Shoaib, M., Holloway, H. W., Ingram, D. K., Wallace, W. C., Haroutunian, V., ... Greig, N. H. (2002). Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat. Journal of Alzheimer's Disease, 4(5), 405-415.

Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat. / Utsuki, Tadanobu; Shoaib, Mohammed; Holloway, Harold W.; Ingram, Donald K.; Wallace, William C.; Haroutunian, Vahram; Sambamurti, Kumar; Lahiri, Debomoy; Greig, Nigel H.

In: Journal of Alzheimer's Disease, Vol. 4, No. 5, 10.2002, p. 405-415.

Research output: Contribution to journalArticle

Utsuki, T, Shoaib, M, Holloway, HW, Ingram, DK, Wallace, WC, Haroutunian, V, Sambamurti, K, Lahiri, D & Greig, NH 2002, 'Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat', Journal of Alzheimer's Disease, vol. 4, no. 5, pp. 405-415.
Utsuki T, Shoaib M, Holloway HW, Ingram DK, Wallace WC, Haroutunian V et al. Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat. Journal of Alzheimer's Disease. 2002 Oct;4(5):405-415.
Utsuki, Tadanobu ; Shoaib, Mohammed ; Holloway, Harold W. ; Ingram, Donald K. ; Wallace, William C. ; Haroutunian, Vahram ; Sambamurti, Kumar ; Lahiri, Debomoy ; Greig, Nigel H. / Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat. In: Journal of Alzheimer's Disease. 2002 ; Vol. 4, No. 5. pp. 405-415.
@article{091abde91fd24243980b5cc102932f1f,
title = "Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat",
abstract = "Reports of an inverse relationship between nicotine intake, due to cigarette smoking, and the incidence of Alzheimer's disease (AD) prompted us to investigate the effects of nicotine on amyloid β-protein precursor (AβPP) processing in rat. Overproduction and/or altered metabolism of AβPP, resulting in increased amyloid β-peptide (Aβ), appear pivotal in the pathogenesis of AD. Aβ is generated proteolytically from AβPP by a group of secretases. AβPP cleavage by γ-secretase results in the secretion of a truncated soluble AβPP (sAPPγ) that contains intact Aβ. Nicotine, 1 and 8 mg/kg/day, doses commensurate with cigarette smoking and a higher but well tolerated dose, respectively, was administered over 14 days and Western blot analysis was performed on sAPP fragments. Both doses significantly reduced sAPPγ. These actions were blocked by nicotinic receptor antagonism. Whereas nicotinic antagonists alone had no effect on either total sAPP or sAPPγ levels in CSF, muscarinic antagonism significantly elevated them; suggesting that muscarinic rather than nicotinic receptor silence alters processing of AβPP to favor a potentially amyloidogenic route. Combined nicotine and muscarinic antagonism attenuated the action of the latter to elevate sAPPγ, indicating that nicotine modifies AβPP processing away from potentially amyloidogenic products. These results suggest that within the brain, levels of total sAPP, sAPPγ and, accordingly, Aβ are subject to cholinergic manipulation, offering therapeutic potential at the level of AβPP processing to decrease Aβ deposition.",
keywords = "β-peptide, Alzheimer's dementia, Amyloid, Cholinergic system, Neuroprotection, Nicotine drug abuse, Scopolamine, Smoking",
author = "Tadanobu Utsuki and Mohammed Shoaib and Holloway, {Harold W.} and Ingram, {Donald K.} and Wallace, {William C.} and Vahram Haroutunian and Kumar Sambamurti and Debomoy Lahiri and Greig, {Nigel H.}",
year = "2002",
month = "10",
language = "English",
volume = "4",
pages = "405--415",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "5",

}

TY - JOUR

T1 - Nicotine lowers the secretion of the Alzheimer's amyloid β-protein precursor that contains amyloid β-peptide in rat

AU - Utsuki, Tadanobu

AU - Shoaib, Mohammed

AU - Holloway, Harold W.

AU - Ingram, Donald K.

AU - Wallace, William C.

AU - Haroutunian, Vahram

AU - Sambamurti, Kumar

AU - Lahiri, Debomoy

AU - Greig, Nigel H.

PY - 2002/10

Y1 - 2002/10

N2 - Reports of an inverse relationship between nicotine intake, due to cigarette smoking, and the incidence of Alzheimer's disease (AD) prompted us to investigate the effects of nicotine on amyloid β-protein precursor (AβPP) processing in rat. Overproduction and/or altered metabolism of AβPP, resulting in increased amyloid β-peptide (Aβ), appear pivotal in the pathogenesis of AD. Aβ is generated proteolytically from AβPP by a group of secretases. AβPP cleavage by γ-secretase results in the secretion of a truncated soluble AβPP (sAPPγ) that contains intact Aβ. Nicotine, 1 and 8 mg/kg/day, doses commensurate with cigarette smoking and a higher but well tolerated dose, respectively, was administered over 14 days and Western blot analysis was performed on sAPP fragments. Both doses significantly reduced sAPPγ. These actions were blocked by nicotinic receptor antagonism. Whereas nicotinic antagonists alone had no effect on either total sAPP or sAPPγ levels in CSF, muscarinic antagonism significantly elevated them; suggesting that muscarinic rather than nicotinic receptor silence alters processing of AβPP to favor a potentially amyloidogenic route. Combined nicotine and muscarinic antagonism attenuated the action of the latter to elevate sAPPγ, indicating that nicotine modifies AβPP processing away from potentially amyloidogenic products. These results suggest that within the brain, levels of total sAPP, sAPPγ and, accordingly, Aβ are subject to cholinergic manipulation, offering therapeutic potential at the level of AβPP processing to decrease Aβ deposition.

AB - Reports of an inverse relationship between nicotine intake, due to cigarette smoking, and the incidence of Alzheimer's disease (AD) prompted us to investigate the effects of nicotine on amyloid β-protein precursor (AβPP) processing in rat. Overproduction and/or altered metabolism of AβPP, resulting in increased amyloid β-peptide (Aβ), appear pivotal in the pathogenesis of AD. Aβ is generated proteolytically from AβPP by a group of secretases. AβPP cleavage by γ-secretase results in the secretion of a truncated soluble AβPP (sAPPγ) that contains intact Aβ. Nicotine, 1 and 8 mg/kg/day, doses commensurate with cigarette smoking and a higher but well tolerated dose, respectively, was administered over 14 days and Western blot analysis was performed on sAPP fragments. Both doses significantly reduced sAPPγ. These actions were blocked by nicotinic receptor antagonism. Whereas nicotinic antagonists alone had no effect on either total sAPP or sAPPγ levels in CSF, muscarinic antagonism significantly elevated them; suggesting that muscarinic rather than nicotinic receptor silence alters processing of AβPP to favor a potentially amyloidogenic route. Combined nicotine and muscarinic antagonism attenuated the action of the latter to elevate sAPPγ, indicating that nicotine modifies AβPP processing away from potentially amyloidogenic products. These results suggest that within the brain, levels of total sAPP, sAPPγ and, accordingly, Aβ are subject to cholinergic manipulation, offering therapeutic potential at the level of AβPP processing to decrease Aβ deposition.

KW - β-peptide

KW - Alzheimer's dementia

KW - Amyloid

KW - Cholinergic system

KW - Neuroprotection

KW - Nicotine drug abuse

KW - Scopolamine

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=0036813113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036813113&partnerID=8YFLogxK

M3 - Article

C2 - 12446972

AN - SCOPUS:0036813113

VL - 4

SP - 405

EP - 415

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 5

ER -